Skip to main content

Table 7 Effect of hypertonic saline and furosemide on urinary electrolytes and proteins in two spot urinary sample after examination in a randomized, cross-over study of 24 healthy subjects

From: Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

 

Spot 1 (day 1 post examination)

Spot 2 (day 3–5 post examination)

U-Na (mmol/L)

 Placebo

79 (41;105)

50 (31;135)

 Furosemide

57 (27;98)

62 (32;151)*

U-K (mmol/L)

 Placebo

26 (15;37)

27 (14;44)

 Furosemide

34 (19;52)

30 (17;58)*

U-Cl (mmol/L)

 Placebo

78 (53;126)

63 (40;129)

 Furosemide

67 (38;116)

70 (45;186)

U-Creatinine (mmol/L)

 Placebo

4 (3;6)

5 (4;16)

 Furosemide

8 (4;13)

5 (3;13)*

U-Osmolality (mmol/L)

 Placebo

392 (200;467)

269 (195;710)*

 Furosemide

430 (236;663)

358 (214;740)*

U-Albumin (mg/L)

 Placebo

2 (1;5)

4 (2;7)

 Furosemide

5 (3;6)

4 (2;4)

U-ENaCγ (ng/ml)

 Placebo

0.29 (0.18;0.44)

0.35 (0.19;0.85)

 Furosemide

0.57 (0.27;0.92)

0.37 (0.21;0.92)

U-AQP2 (ng/ml)

 Placebo

0.40 (0.19;0.49)

0.37 (0.26;0.81)*

 Furosemide

0.68 (0.27;0.95)

0.36 (0.29;1.08)*

U-NGAL (ng/ml)

 Placebo

8.5 (3.8;23.8)

9.5 (2.8;22.3)*

 Furosemide

19.5 (4.0;40.5)

14.0 (3.0;25.5)*

U-KIM (ng/ml)

 Placebo

0.13 (0.08;0.17)

0.22 (0.09;0.35)*

 Furosemide

0.40 (0.09;0.57)

0.20 (0.08;0.49)*

  1. u-Na Urinary concentrations of sodium, u-K potassium, u-Cl chloride, creatinine, albumin, u-ENaCγ γ-fraction of the epithelial sodium channel, u-AQP2 aquaporin 2, u-NGAL neutrophil gelatinase-associated lipocalin and u-KIM-1 kidney injury, molecule-1. Data are shown as medians with 25 and 75 percentiles in brackets. Wilcoxon signed rank test was used to test statistically significant difference from spot 1, * = p < 0.05, and from Placebo,  = p < 0.05